Targeted Radionuclide Therapy (TRT) is an innovative approach to cancer treatment that combines the precision of targeted therapies with the cytotoxic power of radiation. TRT employs radiopharmaceuticals, molecules that selectively bind to tumour cells and deliver radiation directly to the tumour, minimising damage to healthy tissue. As a result, TRT offers improved patient outcomes and fewer side effects compared to conventional cancer treatments. In this article, we will discuss the principles of TRT, its advantages, and potential future developments.
Principles of Targeted Radionuclide Therapy
TRT involves using a vector molecule, such as an antibody, peptide, or small molecule, which binds to specific cancer cell receptors or antigens. This vector molecule is conjugated to a radioactive isotope, such as Lutetium-177 (¹⁷⁷Lu), Yttrium-90 (⁹⁰Y), or Radium-223 (²²³Ra), creating a targeted radiopharmaceutical. Once administered, the radiopharmaceutical circulates throughout the body, binding specifically to cancer cells and delivering targeted radiation to the tumour.
The radiation emitted by the radioactive isotope causes localised ionisation events, resulting in DNA damage, generation of reactive oxygen species, and subsequent cell death. Therefore, the choice of the radioactive isotope depends on the specific properties required for effective treatment, such as the type and energy of radiation emitted, half-life, and chemical compatibility with the vector molecule.
Advantages of Targeted Radionuclide Therapy
There are several advantages of TRT over traditional cancer therapies, such as chemotherapy and external beam radiation therapy:
Future Developments and Conclusion
Research into TRT is rapidly expanding, with numerous clinical trials investigating its safety and efficacy in various cancer types. As our understanding of TRT improves, advancements in vector molecule design, isotope production, and dosimetry may further enhance this treatment modality’s therapeutic efficacy and safety profile.
Combining TRT with other cancer treatments, such as immunotherapy, targeted therapies, or chemotherapy, could lead to synergistic effects and improved patient outcomes. Additionally, the development of theranostic approaches, which combine diagnostic imaging and therapy in a single radiopharmaceutical, holds great potential for personalised medicine and treatment monitoring.
You are here:
home »
Radionuclide Therapy Effects include potential organ toxicity, requiring careful monitoring to manage patient outcomes effectively.
Radionuclide Therapy Effects Uncovered: The Hidden Impact on Our Organs Read Post »
Tritium radiosynthesis enables precise tracking in scientific research, offering critical insights into biochemical pathways and drug development.
Tritium Radiosynthesis: Illuminating the Pathways of Science and Innovation Read Post »
Cancer radiotheranostics combines targeted radiotherapy and diagnostic imaging to provide personalised, precise, and effective cancer treatment.
Cancer Radiotheranostics: The Future of Targeted Cancer Therapy Read Post »
Radiotheranostic treatments combine diagnostic imaging with targeted radiopharmaceutical therapy, providing personalised cancer care with enhanced precision and effectiveness.
Radiotheranostic Treatments: A Guide to Types and Their Clinical Applications Read Post »
Alpha particles provide precise cancer treatment by delivering high-energy radiation, targeting tumour cells while sparing healthy tissue.
The Role of Alpha Particles in Radiotheranostics Read Post »
The article explores the theranostic applications of Terbium radionuclides, highlighting their diagnostic and therapeutic potential in nuclear medicine.
Terbium Radionuclides for Theranostic Applications in Nuclear Medicine Read Post »
Peptide Receptor Radionuclide Therapy offers a targeted approach to treating neuroendocrine tumours, improving survival rates and quality of life.
Advances in Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours Read Post »
Auger electrons, crucial in surface science and medical physics, enable detailed material characterisation and targeted cancer therapies.
The Fascinating World of Auger Electrons: From Discovery to Modern Applications Read Post »
Alpha particles, with high ionising power and low penetration, significantly impact biological tissues when internalised in the body.
Alpha Particles: Their Properties, Sources, Interactions, and Applications Read Post »
Dosimetry in radionuclide therapy plays a crucial role in optimising treatment effectiveness and ensuring patient safety and well-being.
Precision in Treatment: The Role of Dosimetry in Radionuclide Therapy Read Post »
Targeted Alpha Radionuclide Therapy precisely delivers potent alpha particles to tumors, maximising efficacy while sparing healthy tissues.
The Role of Targeted Alpha Radionuclide Therapy in Modern Oncology Read Post »
Q&A – Medical Imaging Modalities and Therapy explores innovative techniques and advancements in diagnostic and therapeutic imaging applications.
Iodine-131 IMAZA innovatively binds to adrenal cortex enzymes, revolutionizing the treatment and imaging of adrenocortical carcinoma effectively.
Iodine-131 ICF01012, targeting melanin receptors, shows promise in the fight against metastasised melanomas, heralding a new era in treatment.
Iodine-131 chTNT, aiming to revolutionise oncology, shows promise in targeting and eradicating tumour cells with precision.
Exploring Iodine-131 chTNT: A Beacon of Hope in Cancer Treatment Read Post »
Iodine-131 CAM-H2 heralds a new era in oncology, offering hope through precise targeting of HER2-expressing cancers with minimal side effects.
Exploring Iodine-131 CAM-H2 for Treating HER2-Expressing Cancers Read Post »
Iodine-131 BA52, a melanin-binding therapeutic, offers new hope for patients with melanin-positive malignant melanomas.
Exploring Iodine-131 BA52: A Novel Melanin-Targeted Therapy for Malignant Melanomas Read Post »
Targeting Blood Cancers: The Role of Iodine-131 Apamistamab in Revolutionising Treatment for AML and Beyond
The Role of Iodine-131 Apamistamab for Acute Myeloid Leukaemia Read Post »
World Theranostics Day honours Dr. Hertz’s groundbreaking radioiodine therapy, transforming disease treatment globally since 1941.
Celebrating World Theranostics Day Honoring Saul Hertz Read Post »
Iodine-131 Monoclonal Antibody 81C6 specifically targets glioma cells by honing in on the tenascin protein.
Iodine-131 Monoclonal Antibody 81C6 Targets Glioma Cells Read Post »
Holmium-166 Phytate, initially developed for chronic synovitis, has shown significant promise in phase I/II clinical trials.
Holmium-166 Phytate Offers a Promising Treatment Option for Chronic Synovitis Read Post »
Holmium-166 Chitosan, a groundbreaking radiopharmaceutical, offers new hope in treating hepatocellular carcinoma with targeted therapy.
Holmium-166 Chitosan in Radiopharmaceutical Cancer Treatment Read Post »
Copper-67 SARTATE emerges as a groundbreaking radiopharmaceutical in targeted cancer therapy, showcasing promising clinical trial results.
Unlocking the Potential of Copper-67 SARTATE in Targeted Radiopharmaceutical Therapy Read Post »
Copper-67 SARbisPSMA offers new hope in targeting and treating prostate cancer with precision and effectiveness.
Copper-67 SARbisPSMA New Frontier in Prostate Cancer Treatment Read Post »
Copper-64 Diasparagine offers a promising breakthrough in targeting and treating aggressive brain tumours like glioblastoma.
213Bi-Lintuzumab demonstrated efficacy in AML treatment, offering a targeted approach with manageable side effects, yet development paused.
Bismuth-213 Lintuzumab: A Promising Treatment for Acute Myeloid Leukaemia Read Post »
211At-Parthanatine, targeting PARP1 with alpha radiation, promises precise cancer therapy, especially for high-risk neuroblastomas.
211At-MX35-F(ab’)2 shows promise in treating ovarian cancer through targeted therapy in ongoing clinical trials.
The Potential of Astatine-211-MX35-F(ab’)2 in Ovarian Cancer Treatment Read Post »
Theragnomics melds theranostics and radiomics, promising targeted cancer therapies with improved outcomes through precision diagnostics and treatment adaptation.
Combining Theranostics and Radiomics: The Emergence of Theragnomics Read Post »
Therapeutic nuclear medicine leverages radionuclides for targeted cancer treatment, facing challenges in delivery, safety, and regulatory compliance.
Neuroblastoma Targeting Agents offer innovative diagnostic and therapeutic options, revolutionizing treatment with precise targeting and efficacy.
Neuroblastoma Targeting Agents: An Insight into Diagnostic and Therapeutic Advances Read Post »
Technetium-99m and Radium-223 are pivotal in managing bone metastases, enhancing both diagnostic accuracy and therapeutic efficacy.
211At-BC8-B10, targeting CD45 in leukemia, combines BC8 antibody with Astatine-211, showing promising clinical trials.
Astatine-211 BC8-B10: A Promising Radioimmunoconjugate for Leukaemia Treatment Read Post »
Astatine-211 in radiotheranostics offers targeted, effective cancer treatment, but faces production and safety challenges.
Astatine-211 Radiotheranostics: A New Era in Cancer Treatment Read Post »
225Ac-PSMA-617 revolutionises prostate cancer treatment, offering targeted, effective therapy with promising clinical trial results.
Actinium-225 PSMA-617: Revolutionising Prostate Cancer Treatment Read Post »
225Ac-Lintuzumab, targeting CD33, shows promise in AML treatment with potential expansion to other cancers.
Actinium-225 Lintuzumab: A Breakthrough in Acute Myeloid Leukaemia Treatment Read Post »
Actinium-225 is a rare, promising isotope revolutionizing targeted alpha therapy for various resistant cancers.
Actinium-225: The Emerging Star in Targeted Alpha Therapy Read Post »
225Ac-FPI-2068 and 111In-FPI-2107 represent a major advancement in targeted alpha therapy for various solid tumours.
Lutetium-177 Dotatate selectively binds to SSTRs on NET cells, delivering targeted radiation, minimizing collateral damage, and reducing side effects.
Lutetium-177 Dotatate: A Novel Therapeutic Approach in Neuroendocrine Tumours Read Post »
Indium-111 Pentetate enables tumour detection, infection, inflammation tracking, and cerebrospinal fluid leak identification.
Indium-111 Pentetate: Targeted Therapy in Oncology, Infection, and Inflammation Read Post »
Topics on PET imaging, automated radiosynthesis, breast cancer, prostate cancer therapy and ultrasound.
Inaugural editorial review: nuclear medicine, diagnostic imaging and therapy Read Post »
